Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

The Pharma Data

DECEMBER 18, 2020

Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Director of the FDA’s Center for Biologics Evaluation and Research. SILVER SPRING, Md. ,

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., Casirivimab and imdevimab injection is not FDA approved for any use. cardiovascular disease, OR. chronic obstructive pulmonary disease/other chronic respiratory disease.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 17, 2020

Authorized Emergency Use Casirivimab and imdevimab injection is an investigational combination therapy and has been authorized by FDA for the emergency use described above. Casirivimab and imdevimab injection is not FDA approved for any use. Have chronic kidney disease. Have immunosuppressive disease.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. Regeneron has shared these results with the U.S.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 11, 2020

Centers for Disease Control and Prevention (CDC), will manage allocation and distribution of the vaccine in the U.S. This will be prioritized according to the populations identified by the CDC’s Advisory Committee on Immunization Practices (ACIP) guidelines. CEO and Co-founder of BioNTech.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 27, 2020

This year has been difficult, but it has reinforced the importance of our mission: to treat and potentially even reverse the effects of serious diseases and conditions by advancing our novel cell therapy product candidates through clinical trials and into the hands of physicians.

Therapies 52

Therapies Clinical Trials Production Treatment 52

The Pharma Data

DECEMBER 10, 2020

These pivotal data demonstrate that our COVID-19 vaccine candidate is highly effective in preventing COVID-19 disease and is generally well-tolerated. The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review.

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

The Pharma Data

OCTOBER 14, 2020

Additionally, immunogenicity, duration of immune response and occurrence of symptomatic COVID-19 will be measured. is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. About ImmunityBio ImmunityBio, Inc.

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

New Drug Approvals

DECEMBER 16, 2023

2 This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene. 2 This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene. of patients experienced a sustained hemoglobin improvement without transfusions respectively. 5 December 2023.

FDA 62

FDA Small Molecule FDA Approval Clinical Trials 62

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Have chronic kidney disease.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Have chronic kidney disease. cardiovascular disease, OR.

FDA 40

FDA Clinical Trials Hospitals Government 40

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

APRIL 27, 2021

Rare Disease. Others Rare Disease. Total Rare Disease. In the first quarter, Rare Disease sales increased 4.4% At the end of March, the FDA approved Sarclisa ® in combination with carfilzomib and dexamethasone for patients with relapsed multiple myeloma. Net sales (€ million). Change at CER. Fabrazyme ®.

Vaccine 52

Vaccine Production FDA FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

“The results we have announced today demonstrate the potential of the combination of TG4001 with an immune checkpoint inhibitor in this particularly severe disease setting. We observed very encouraging responses rates, as high as 34.8 % in patients who did not have liver metastases. Methods.

Vaccine 52

Vaccine Virus Trials Treatment 52

The Pharma Data

AUGUST 11, 2020

Responses to the current standard chemotherapy in patients are short lived, and less than 6% of patients with metastatic disease survive beyond five years,” said Yelena Y. All patients continued treatment for two years or until disease progression, unacceptable toxicity or withdrawal of consent. Janjigian, M.D., About Opdivo.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

FEBRUARY 24, 2022

The Committee considered that the available evidence was sufficient to conclude that the immune response to a booster dose in adolescents would be at least equal to that in adults. No new safety concerns were identified from the data available. For more than 170 years, we have worked to make a difference for all who rely on us.

Vaccine 52

Vaccine FDA Small Molecule Immune Response 52

The Pharma Data

JANUARY 29, 2021

Prevention of severe disease; protection against COVID-related hospitalization and death The vaccine candidate was 85 percent effective in preventing severe disease across all regions studied, [i] 28 days after vaccination in all adults 18 years and older. Global Head, Janssen Research & Development.

Vaccine 40

Vaccine Trials Pharmaceutical Companies Immune Response 40

Codon

APRIL 23, 2023

Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. These ribonucleoproteins also caused a lower immune response compared to the viruses, and are much easier to make in the lab. Malaria mortality from 2000 (left) to 2019 (right).

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 23, 2023

Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. These ribonucleoproteins also caused a lower immune response compared to the viruses, and are much easier to make in the lab. Malaria mortality from 2000 (left) to 2019 (right).

Vaccine 52

Vaccine DNA Virus Engineering 52